SEC Tracker
Get the app

Achilles Therapeutics

Julie O'Neill (Former Director) plans to sell 38,750 shares, about $53,107

Form
144
Filed
Importance
Routine
Document
Form 144
  1. Approximate sale date: Feb 4, 2025
  2. Broker: Citigroup Capital Markets, Inc.
  3. Shares acquired by: Option scheme

All of Julie O'Neill's insider filings, holdings and planned sales

Written from the Form 144 on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Achilles Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2836) and public float not reported.

  1. Adaptimmune Therapeutics ADAP
  2. Adverum Biotechnologies ADVM
  3. AgomAb Therapeutics AGMB
  4. Alvotech ALVO
  5. Argenx ARGX